135 related articles for article (PubMed ID: 22123108)
21. COMT inhibitors in Parkinson's disease.
Rivest J; Barclay CL; Suchowersky O
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S34-8. PubMed ID: 10451758
[TBL] [Abstract][Full Text] [Related]
22. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis.
Sun J; Von Tungeln LS; Hines W; Beger RD
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(24):2557-65. PubMed ID: 19615953
[TBL] [Abstract][Full Text] [Related]
23. An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma.
Gonçalves D; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Analyst; 2013 Apr; 138(8):2463-9. PubMed ID: 23476919
[TBL] [Abstract][Full Text] [Related]
24. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
[TBL] [Abstract][Full Text] [Related]
25. Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.
Ménnistó PT
CNS Drugs; 1994 Mar; 1(3):172-9. PubMed ID: 27520516
[TBL] [Abstract][Full Text] [Related]
26. Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans.
Zürcher G; Da Prada M; Dingemanse J
Biomed Chromatogr; 1996; 10(1):32-6. PubMed ID: 8821869
[TBL] [Abstract][Full Text] [Related]
27. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
St Onge E; Vanderhoof M; Miller S
Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
[TBL] [Abstract][Full Text] [Related]
28. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a HPLC electrochemical detection method to measure COMT activity as a tool in drug development.
Viljoen FP; Preez JLD; Petzer A; Wessels JC; Petzer J; Aucamp ME
Pharmazie; 2019 May; 74(5):270-276. PubMed ID: 31109396
[TBL] [Abstract][Full Text] [Related]
30. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.
Wikberg T; Vuorela A; Ottoila P; Taskinen J
Drug Metab Dispos; 1993; 21(1):81-92. PubMed ID: 8095232
[TBL] [Abstract][Full Text] [Related]
31. Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.
Gonçalves D; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Biomed Chromatogr; 2016 Mar; 30(3):312-22. PubMed ID: 26147707
[TBL] [Abstract][Full Text] [Related]
32. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
Kiss LE; Soares-da-Silva P
J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080
[TBL] [Abstract][Full Text] [Related]
33. Validation of assay of catechol-O-methyltransferase activity in human erythrocytes.
Tuomainen P; Reenilä I; Männistö PT
J Pharm Biomed Anal; 1996 Mar; 14(5):515-23. PubMed ID: 8738181
[TBL] [Abstract][Full Text] [Related]
34. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Heizmann P; Schmitt M; Leube J; Martin H; Saner A
J Chromatogr B Biomed Sci Appl; 1999 Jul; 730(2):153-60. PubMed ID: 10448949
[TBL] [Abstract][Full Text] [Related]
35. Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone.
Silva TB; Borges F; Serrão MP; Soares-da-Silva P
Drug Discov Today; 2020 Oct; 25(10):1846-1854. PubMed ID: 32687872
[TBL] [Abstract][Full Text] [Related]
36. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.
Palma PN; Bonifácio MJ; Loureiro AI; Wright LC; Learmonth DA; Soares-da-Silva P
Drug Metab Dispos; 2003 Mar; 31(3):250-8. PubMed ID: 12584150
[TBL] [Abstract][Full Text] [Related]
37. Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-[(2,4-Dichlorophenyl)methyl]-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach.
Subair TI; Akawa OB; Soremekun OS; Olotu FA; Soliman MES
Chem Biodivers; 2021 Sep; 18(9):e2100204. PubMed ID: 34252268
[TBL] [Abstract][Full Text] [Related]
38. Opicapone for the treatment of Parkinson's disease.
Rodrigues FB; Ferreira JJ
Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
[TBL] [Abstract][Full Text] [Related]
39. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations.
Palma PN; Bonifácio MJ; Loureiro AI; Soares-da-Silva P
J Comput Chem; 2012 Apr; 33(9):970-86. PubMed ID: 22278964
[TBL] [Abstract][Full Text] [Related]
40. Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides.
Luukkanen L; Kilpeläinen I; Kangas H; Ottoila P; Elovaara E; Taskinen J
Bioconjug Chem; 1999; 10(1):150-4. PubMed ID: 9893978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
